期刊文献+

pre-hsa-miR-98对卵巢癌细胞增殖活性抑制的影响 被引量:3

Inhibitory effect of pre-hsa-miR-98 transfection on the proliferation of ovarian cancer cell lines
下载PDF
导出
摘要 目的卵巢癌的死亡率占各类妇科恶性肿瘤的首位,对女性患者的生命造成严重威胁。miR-98可抑制多种癌细胞增殖,但未见关于其应用于卵巢癌治疗的报道。文中为探讨卵巢癌治疗的新方法,用pre-hsa-miR-98转染卵巢癌SKOV3、HO8910和A2780细胞,观察转染率并研究转染后对卵巢癌细胞的增殖抑制作用。方法利用构建的pre-hsa-miR-98质粒HmiR和连接随机序列的质粒CmiR转染人卵巢癌细胞SKOV3、HO8910和A2780细胞,荧光显微镜与流式细胞仪计数计算转染率,MTT法检测细胞增殖抑制率与细胞计数绘制生长曲线研究转染对卵巢癌细胞的增殖抑制作用。结果转染HmiR后,荧光显微镜观察和流式细胞术计数结果显示SKOV3、HO8910、A2780细胞的转染率均在60%左右。转染HmiR后,MTT法检测SKOV3、HO8910、A2780细胞的增殖抑制率随转染时间延长而增加,72 h分别达到49.54%、53.25%、46.09%。生长曲线显示在72 h及96 h抑制率达到高峰,随后随时间延长抑制率不再显著升高。结论 3种卵巢癌细胞的转染率达到实验要求,HmiR转染后可抑制卵巢癌细胞增殖,其抑制作用随转染时间延长而增强。 Objective Ovarian cancer ranks first in mortality among gynecological malignancies,and poses a vital threat to the lives of the patients.Though miR-98 can inhibit the proliferation of various cancer cell lines,its effect on ovarian cancer has never been reported.This study is to search for a new treatment of ovarian cancer by transfecting pre-hsa-miR-98 into ovarian cancer SKOV3,HO8910 and A2780 cells and observing the transfection efficiency and its inhibitory effect on the proliferation of ovarian cancer cells.Methods The pre-hsa-miR-98 plasmid HmiR and plasmid CmiR from a control vector were transfected into human ovarian cancer cell lines SKOV3,HO8910 and A2780.The transfection efficiency was determined by fluorescence microscopy and flow cytometry,and the inhibitory effect on the proliferation of the cell lines detected by MTT assay and the cell count growth curve.Results After HmiR transfection,the rates of transfection in SKOV3,HO8910 and A2780 cell lines were all about 60%,and the rates of the cell proliferation inhibition rose with the increased time of transfection,up to 49.54%,53.25%,and 46.09% after 72 hours of transfection.The cell growth inhibition reached the peak at 72 and 96 hours after the treatment,and thereafter exhibited no significant rise with the increase of time.Conclusion The rates of transfection of the three ovarian cancer cell lines by pre-hsa-miR-98 HmiR were all up to the experimental requirements,and the transfection inhibited the proliferation of ovarian cancer cell lines in a time-dependent manner.
出处 《医学研究生学报》 CAS 2011年第7期691-695,共5页 Journal of Medical Postgraduates
基金 山东省自然科学基金(Y2008C162)
关键词 miR-98 卵巢癌细胞 转染率 增殖抑制 pre-miR-98 Ovarian cancer cell Transfection Proliferation inhibition
  • 相关文献

参考文献8

  • 1马荣,唐丽萍,耿晓星,傅松滨.沉默survivin对增加晚期宫颈癌基因放疗效果的实验研究[J].医学研究生学报,2010,23(7):692-696. 被引量:3
  • 2高峰,陈莎莎,徐懋,刘希江,吴震,曹菲,许爱军,田学愎,田玉科,杨辉.β-arrestin2抗基因RNA表达载体的构建及其基因沉默效应鉴定[J].医学研究生学报,2010,23(6):575-578. 被引量:4
  • 3王树军,唐元家,崔慧娟,赵遐,王立珈,钱晓霞,黄新芳,陈顺乐,沈南.let-7/miR-98家族对Fas基因的调节作用[J].现代免疫学,2010,30(3):177-182. 被引量:4
  • 4Sukata T,Sumida K,Kushida M,et al.Circulating microRNAs,possible indicators of progress of rat hepatocarcinogenesis from ear-ly stages. Toxicology Letters . 2011
  • 5Du L,Schageman JJ,Subauste MC,et al.miR-93,miR-98,andmiR-197 Regulate Expression of Tumor Suppressor Gene FUS1. Molecular Cancer Research . 2009
  • 6Bhat-Nakshatri P,Wang G,Collins NR,et al.Estradiol-regulatedmicroRNAs control estradiol response in breast cancer cells. Nucleic Acids Research . 2009
  • 7Resnick KE,Alder H,Hagan JPet al.The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecologic Oncology . 2009
  • 8Yan L X,Huang X F,Shao Q,et al.MicroRNA miR-21overexpression in human breast cancer is associated with advanced clinical stage,lymph node metastasis and patient poor prognosis. Rádio Nacional de Angola . 2008

二级参考文献53

  • 1崔慧娟,唐元家,罗晓兵,邓筠,郭彦芝,黄新芳,陈顺乐,沈南.系统性红斑狼疮患者中miR-146a表达缺陷与I型干扰素通路过度活化相关[J].现代免疫学,2008,28(4):279-284. 被引量:13
  • 2马荣,陈曦海,张岂凡,朱镭,唐丽萍,王晶,成海燕,雷利娜.反义survivin核酸增强胃癌细胞对多西他赛敏感性及其逆转耐药机制的探讨[J].中华肿瘤杂志,2007,29(2):89-92. 被引量:11
  • 3Kertesz M, Iovino N, Unnerstall U,et al. The role of site accessibility in microRNA target recognition[J]. Nat Genet, 2007,39:1278 -1284.
  • 4Watanabe-Fukunaga R, Brannan CI, Copeland NG, et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis[J].Nature, 1992,356: 314-317.
  • 5Cianga C, Cianga P, Cozma L,et al. The significance of Fas/ FasL molecular system in breast cancer[J]. Rev Med Chir Soc Med Nat Iasi, 2004,108:440-444.
  • 6Chopin V, Toillon RA, Jouy N, et al. Sodium butyrate induces P53 independent, Fas mediated apoptosis in MCF-7 human breast cancer cells[J]. Br J Pharmacol, 2002, 135: 79-86.
  • 7Yoshimoto Y, Kawada M, Ikeda D, et al. Involvement of doxorubicin induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo[J]. Int Immunopharmacol, 2005,5 :281-288.
  • 8Nozawa K, Kayagaki N, Tokano Y, et al. Soluble Fas (APO1, CD95) and soluble Fas ligand in rheumatic diseases [J]. Arthritis Rheum, 1997,40:1126-1129.
  • 9Ates A, Kinikli G, Turgay M,et al. The levels of serum soluble Fas in patients with rheumatoid arthritis and systemic sclerosis[J]. Clin Rheumatol, 2004,23:421 -425.
  • 10Sahin M, Aydintug O, Tunc SE,et al. Serum soluble Fas levels in patients with autoimmune rheumatic diseases[J].Clin Biochem, 2007,40:6-10.

共引文献8

同被引文献64

  • 1李芳秋,杨爱龙,缪家文,张春华,吴波,张新华.人精子蛋白17单克隆抗体的制备及特性鉴定[J].细胞与分子免疫学杂志,2006,22(5):638-640. 被引量:13
  • 2刘东,饶子超,陈兆聪.紫杉醇与抗HER2单抗Sc7301偶联物对肿瘤细胞株的体外杀伤效应[J].中国医院药学杂志,2007,27(1):10-13. 被引量:6
  • 3Martin L, Schilder R. Novel approaches in advancing the treatment of epithelial ovarian cancer: The role of angiogenesis inhibition[J]. J Clin Oncol, 2007, 25 (20):2894-2901.
  • 4Burke PJ, Toki BE, Meyer DW, et al. Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system[J]. BioorgMed Chem Lett, 2009, 19(10): 2650-2653.
  • 5Sergio A, Roberto S. Monoclonal antibodies and immunoconjugates in acute myeloid leukemia[J]. Best Pract Res Clin Haematol, 2006, 19(4):715-801.
  • 6Madiyalakan R, Sykes TR, Dharampaul S, et al. Antiidiotype induction therapy: Evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13[J]. Hybridoma, 1995, 14(2): 199-203.
  • 7Peng S, Maihle NJ, Huang Y. Pluripotency factors Lin28 and Oct4 identify a sub- population of stem cell-like cells in ovarian cancer[J]. Oncogene, 2010, 29(14):2153- 2159.
  • 8Lonberg N. Human antibodies from transgenic animals[J]. Nature biotechnology, 2005, 23(9): 1117-1125.
  • 9Oei LM, Sweep CG, Thomas MG, et al. The use of monoclonal antibodies for the treatment of epithelial ovarian cancer[J]. Int J Oncology, 2008, 32(6): 1145-1157.
  • 10Wagner UA, Oehr PF, Reinsberg J, et al. Immunotherapy of advanced ovarian carcinomas by activation of the idiotypic network[J]. Biotechnol Ther, 1992, 3(1-2): 81-89.

引证文献3

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部